RESEARCH TRIANGLE PARK, N.C., April 07, 2026 (GLOBE NEWSWIRE) — Merakris Therapeutics today provided an update on recent communications with the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug (IND) application for MTX-001, an investigational biologic being developed for venous leg ulcers (VLUs).